TrialA Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
Trial details
- Registry ID
- NCT02836574
- Phase
- Phase 2
PROK
Prokidney
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
4Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney DiseaseNCT02836574 | Prokidney | Phase 2 | Completed | 2023-12Actual |
| A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney DiseaseNCT03270956 | Prokidney | Phase 2 | Completed | 2022-11-17Actual |
| Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)NCT05018416 | Prokidney | Phase 2 | Completed | 2025-05-20Actual |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney DiseaseNCT05099770 | Prokidney | Phase 3 | Active not recruiting | 2029-12Estimated |
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
Trial details
- Registry ID
- NCT03270956
- Phase
- Phase 2
Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007)
Trial details
- Registry ID
- NCT05018416
- Phase
- Phase 2
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Trial details
- Registry ID
- NCT05099770
- Phase
- Phase 3
Latest recorded trial changes
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770 · Prokidney
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770 · Prokidney
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Clinical Endpoint
+ After
Measure: Surrogate / Intermediate Efficacy Endpoint -eGFR Slope Measure: Clinical Endpoint
Primary completion date changed
− Before
Feb 2027
+ After
Dec 2029
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
NCT05099770 · Prokidney
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: Primary Composite Endpoint
+ After
Measure: Clinical Endpoint